Granisetron Patent Expiration

Granisetron is Used for preventing and treating nausea and vomiting associated with chemotherapy and other conditions. It was first introduced by Cumberland Pharmaceuticals Inc in its drug Sancuso on Sep 12, 2008. Another drug containing Granisetron is Sustol. 2 different companies have introduced drugs containing Granisetron.


Granisetron Patents

Given below is the list of patents protecting Granisetron, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Sancuso US7608282 Transdermal granisetron Jan 22, 2025 Cumberland
Sustol US10357570 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron Sep 28, 2024

(Expired)

Heron Theraps Inc
Sustol US8252304 Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron Sep 28, 2024

(Expired)

Heron Theraps Inc
Sustol US8252305 Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron Sep 28, 2024

(Expired)

Heron Theraps Inc
Sustol US8715710 Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron Sep 28, 2024

(Expired)

Heron Theraps Inc
Sustol US9913910 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron Sep 28, 2024

(Expired)

Heron Theraps Inc
Sustol US6613355 Semi-solid delivery vehicle and pharmaceutical compositions Jun 28, 2021

(Expired)

Heron Theraps Inc
Sustol US6790458 Pharmaceutical compositions using semi-solid delivery vehicle May 11, 2021

(Expired)

Heron Theraps Inc



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Granisetron's patents.

Given below is the list recent legal activities going on the following patents of Granisetron.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Yr, Small Entity 28 Feb, 2024 US8252304
Payment of Maintenance Fee, 12th Yr, Small Entity 28 Feb, 2024 US8252305
Payment of Maintenance Fee, 4th Yr, Small Entity 23 Jan, 2023 US10357570
Payment of Maintenance Fee, 4th Yr, Small Entity 13 Sep, 2021 US9913910
Payment of Maintenance Fee, 12th Year, Large Entity 14 Apr, 2021 US7608282(Litigated)
Payment of Maintenance Fee, 8th Yr, Small Entity 28 Feb, 2020 US8252305
Payment of Maintenance Fee, 8th Yr, Small Entity 28 Feb, 2020 US8252304
Patent Issue Date Used in PTA Calculation 23 Jul, 2019 US10357570
Recordation of Patent Grant Mailed 23 Jul, 2019 US10357570
Email Notification 03 Jul, 2019 US10357570


Granisetron's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List